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SHORT COMMUNICATION
Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin
in normal and neoplastic human cell lines
K.R. Huber', E.P. Mayer2, D.F. Mitchell' & J. Roberts'
'Department ofBasic Pharmaceutical Sciences and 2Department ofMicrobiology/Immunology, University ofSouth Carolina,
Columbia, SC 29208, USA.
The fermentation derived glutamine antimetabolites 6-diazo-
5-oxo-L-norleucine (DON) and [aS, 5S]-a-amino-3-chloro-
4,5-dihydro-5-isoxazoleacetic acid (Acivicin) have been shown
to possess promising antitumour activity against a wide
variety of animal and human xenografted solid tumours
including colon, breast and lung carcinomas (Ovejera et al.,
1979; Houchens et al., 1979; Duvall, 1960). These analogues
of glutamine, however, have limited potential when used as
single agents in the treatment of cancer in man because of
severe toxicity that prevents dose escalation into the required
therapeutic range (Sklaroff et al., 1980; Weiss et al., 1982;
LePage & Loo, 1973). Co-administration of glutamine
reduces markedly the concentration of glutamine in the
tumour-bearing host making it possible to utilize
considerably lower doses of the analogue, and this has
resulted in improvement of the therapeutic index (Roberts &
Rosenfeld, 1980; Roberts et al., 1979; Holcenberg, 1979).
Treatment with glutaminase alone was shown to inhibit
growth of a variety of ascites tumours and leukaemias, but
had only slight efficacy against experimental solid tumours
(Roberts et al., 1979; Schmid & Roberts, 1974; Mitta et al;,
1980). In order to ascertain the extent to which the
therapeutic efficacy of glutamine antimetabolites may be
enhanced by glutamine depletion we studied the effects of
glutamine antagonists on DNA synthesis and cell cycle phase
distributions in normal and malignant cells in culture.
The human cell lines studied were Redmond colon tumour
(doubling time, 1.7 days), and A549 lung tumour (dt, 1.7
days), obtained from the Memorial Sloan-Kettering Cancer
Center, colon tumour cell lines CX-1 (dt, 1.2 days) and CX-2
(dt, 1.2 days), and lung tumour LX-1 (dt, 1.4 days) supplied
by the Frederick Cancer Research Facility, and colon tumour
SKCO-1 (dt, 2.2 days) obtained from the American Type
Culture Collection. The normal human lung fibroblast cell
line IMR-90, obtained from a normal 16 week white female
foetus, was provided by Dr Clive L. Bunn, Dept. Biology,
University of South Carolina. The IMR-90 cell line was
studied at the 26th of 55 generations (dt, 2 days) (Nichols
et al., 1977). Cells were maintained in RPMI medium (KC-
Biological, Lenexa, Kansas) with 10% FCS, 2mM glutamine
and antibiotics at 37°C and 5% C02; they were monitored
for mycoplasma and studied while in midlog phase. Twenty-
four hours after seeding 5 x 105 cells/25cm2 flask, the
cultures were incubated for 48 h with varying amounts of
acivicin, DON, glutaminase or with glutamine-deficient
medium (with and without drugs). Cells from duplicate
cultures at each treatment were harvested by trypsinization
and dispersed into single cell suspensions in fresh RPMI
medium with 10% FCS. Viability cell counts were performed
in 0.2% trypan blue with a haemacytometer to assure growth
of untreated control cultures. All experiments were performed
at least two times.
DON was obtained from the National Cancer Institute
and acivicin from the Upjohn Company. Highly purified
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glutaminase was derived from a soil isolate organism and
assayed as described (Roberts, 1976). The glutamine-depleted
medium consisted of RPMI lacking glutamine and
containing 10% dialyzed FCS. After incubation with acivicin,
DON, glutaminase or glutamine-depleted medium (with and
without drugs) for 48 h, or with acivicin or DON in medium
with glutamine for 2h, 1 1Ci m l radiolabelled [methyl-3H]-
thymidine (NEN, Boston, MA) was added to the cell
cultures. Inhibition of DNA synthesis which has been shown
to reflect the cellular sensitivity to the cytotoxic effects of the
drugs was monitored as described in a previous study
(Rosenfeld & Roberts, 1981). Dose response (0.6-60MM of
drugs) was routinely monitored for all cell lines tested after
2 h incubation with the drugs and 0-90% inhibition could be
observed within this range. Table I shows the sensitivity of
different cell lines to the analogues. Sensitivities are expressed
as concentration of analogues causing 50-60% inhibition of
DNA synthesis as compared to untreated controls. The
values summarize the results of two independent experiments
each performed in duplicate. As shown in Table I, the
tumour cell lines tested were 3-10 times more sensitive to
DON and 2-6 times more sensitive to acivicin than was the
normal lung fibroblast IMR-90 cell lines.
In order to ascertain what effects glutamine depletion and
glutamine antimetabolites would exert upon cell cycle phase
distribution, cells were incubated for 48 h with either
glutamine-depleted medium, glutaminase (0.01 I.U. or 0.1
IUml-1), DON or acivicin (6 or 30pM). These concentra-
tions of drugs completely inhibited growth of all cell lines
tested but cell viability was still unaffected (>90%). Nuclei
were isolated as described (Thornthwaite et al., 1980),
stained with 50pgml-' propidium iodide, and cell cycle
analysis was performed on a Coulter Electronics Epics V
flow cytometer (Coulter Electronics, Inc., Hialeah, FL.). The
instrument was adjusted to achieve coefficients of variation
for the nuclei of usually 3-5%. The proportion of 10,000
nuclei in G1, S, and G2-M was calculated using the Para 1
data analysis program of the flow cytometer. Figure 1 shows
representative histograms obtained with the normal
Table I Sensitivity of normal and neoplastic human cell lines in
culture to DON and acivicin
Concentration (,M) ofantimetabolite
needed to produce 50-60% inhibition
Cell line Acivicin DON
IMR-90 normal fibroblast 29.0 29.2
A549 lung tumour 11.6 9.9
LX-1 lung tumour 4.6 2.6
SKCO-1 colon tumour 11.6 5.8
Redmond colon tumour 11.6 4.6
CX-1 colon tumour 5.8 2.9
CX-2 colon tumour 17.4 5.8
The cells were preincubated for 2 h with the drug before
[3H]thymidine was added at 1 pCiml-'. The values listed refer to
the antimetabolite concentration required to produce 50 to 60%
inhibition ofisotope incorporation, as outlined in the text.
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1). As can be seen in Figure 1 and in Table II, depletion of
glutamine caused slight decreases in the S populations with
concomitant increases in G1 and G2-M in all cell lines.
Although treatment with 30yM DON (or acivicin) depleted
the S-phase fraction in the IMR-90 fibroblast cell line,
striking S-phase blocks were observed when any of the
tumour cell lines were incubated in 30 jM DON. The
strikingly different responses to DON treatment by the IMR-
90 fibroblasts and the tumour cell lines may be related to the
slightly lower S-phase population of the IMR-90 cell line.
The different responses to drug treatment could also be a
reflection of the normal (but not neoplastic) cell's ability to
undergo a negative pleiotypic response when the conditions
in the culture medium are unfavorable to normal growth.
The results with acivicin are in agreement with earlier
reports where it was shown that this analogue blocked cell
cycle progression in GI or early S-phase (Thornthwaite &
Allen, 1980; Jayaram et al., 1975). The effects of DON on cell
cycle phase distribution have not previously been described.
Both DON and acivicin have been shown to inhibit DNA
synthesis by blocking de novo purine and pyrimidine
synthesis (Weber et al., 1982; Lui et al., 1982; Aoki et al.,
1982; Levenberg et al., 1957; Eidinoff et al., 1958). However,
our results indicating different perturbations of the cell cycle
phase distribution by acivicin and DON suggest different
modes of action for these glutamine antimetabolites.
For all cell lines tested the effects of acivicin and DON on
cell cycle phase distribution were more pronounced if the
drugs were added to glutamine-depleted medium containing
dialyzed serum. Drug concentrations of 6 uM, which showed
only slight perturbations in cell cycle distribution when used
in media containing glutamine, exhibited much more pro-
nounced effects in the absence of glutamine, generally
showing increases in the S-phase populations (Table II,
Figure 1).
Our results indicate that depletion of glutamine in the
medium caused enhancement of cell cycle phase perturba-
tions by DON and acivicin and that the normal human lung
fibroblast cell line (IMR-90) was affected differently by the
glutamine antimetabolites than were several human tumour
cell lines. The observation that the perturbations of cell cycle
phase distribution were much more pronounced when the
medium lacked glutamine is therapeutically promising. These
findings reinforce the therapeutic potential of administering
glutamine antimetabolites in combination with a glutamine-
depleting enzyme.
Channel Number x 101
Figure 1 DNA histograms of IMR-90 normal fibroblast and
CX-1 tumour cells: effects of glutamine depletion and glutamine
antimetabolites on cell cycle phase distribution. 24h after
seeding, cells were incubated either in glutamine-deficient
medium, with glutaminase (0.1 lUml-1), acivicin or DON (6 or
30pM). 48 h later cells were harvested and suspended in nuclei This investigation was supported by PHS grant CA-40446 awarded
isolation medium. DNA histograms of 10,000 propidium iodide by the National Cancer Institute, NIH, USA and PCM-8212634
stained nuclei were obtained by flow cytometry. grant awarded by the National Science Foundation, USA.
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